These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 8029800)
1. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Loza JP; Gurewich V; Johnstone M; Pannell R Thromb Haemost; 1994 Mar; 71(3):347-52. PubMed ID: 8029800 [TBL] [Abstract][Full Text] [Related]
2. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. Gurewich V; Johnstone M; Loza JP; Pannell R FEBS Lett; 1993 Mar; 318(3):317-21. PubMed ID: 8440390 [TBL] [Abstract][Full Text] [Related]
3. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Gurewich V; Pannell R Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872 [TBL] [Abstract][Full Text] [Related]
4. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. Pannell R; Black J; Gurewich V J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831 [TBL] [Abstract][Full Text] [Related]
5. Activation of single-chain urokinase-type plasminogen activator by platelet-associated plasminogen: a mechanism for stimulation of fibrinolysis by platelets. Baeten KM; Richard MC; Kanse SM; Mutch NJ; Degen JL; Booth NA J Thromb Haemost; 2010 Jun; 8(6):1313-22. PubMed ID: 20180903 [TBL] [Abstract][Full Text] [Related]
6. Factor XIIa is a kinetically favorable plasminogen activator. Schousboe I; Feddersen K; RĂžjkjaer R Thromb Haemost; 1999 Sep; 82(3):1041-6. PubMed ID: 10494761 [TBL] [Abstract][Full Text] [Related]
7. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents. Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085 [TBL] [Abstract][Full Text] [Related]
8. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Sabovic M; Lijnen HR; Keber D; Collen D Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Kunitada S; FitzGerald GA; Fitzgerald DJ Blood; 1992 Mar; 79(6):1420-7. PubMed ID: 1547340 [TBL] [Abstract][Full Text] [Related]
10. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Torr-Brown SR; Sobel BE Thromb Res; 1993 Dec; 72(5):413-21. PubMed ID: 8303684 [TBL] [Abstract][Full Text] [Related]
11. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Lenich C; Pannell R; Gurewich V Thromb Haemost; 1995 Aug; 74(2):698-703. PubMed ID: 8585009 [TBL] [Abstract][Full Text] [Related]
12. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. Ichinose A; Fujikawa K; Suyama T J Biol Chem; 1986 Mar; 261(8):3486-9. PubMed ID: 3081506 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model. Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137 [TBL] [Abstract][Full Text] [Related]
14. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. Braaten JV; Jerome WG; Hantgan RR Blood; 1994 Feb; 83(4):982-93. PubMed ID: 8111066 [TBL] [Abstract][Full Text] [Related]
15. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Pannell R; Gurewich V Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158). Gurewich V; Pannell R; Broeze RJ; Mao J J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047 [TBL] [Abstract][Full Text] [Related]
17. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species. Lijnen HR; De Wreede K; Demarsin E; Collen D Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261 [TBL] [Abstract][Full Text] [Related]
18. Factor XIIa activation of plasminogen is enhanced by contact activating surfaces and Zn2+. Schousboe I Blood Coagul Fibrinolysis; 1997 Mar; 8(2):97-104. PubMed ID: 9518051 [TBL] [Abstract][Full Text] [Related]
19. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis. Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367 [TBL] [Abstract][Full Text] [Related]
20. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Bork K; Kleist R; Hardt J; Witzke G Blood Coagul Fibrinolysis; 2009 Jul; 20(5):325-32. PubMed ID: 19474702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]